BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37937685)

  • 21. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
    Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
    Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ZNF33A Promotes Tumor Progression and BET Inhibitor Resistance in Triple-Negative Breast Cancer.
    Wang X; Wei X; Cao Y; Xing P
    Am J Pathol; 2022 Oct; 192(10):1458-1469. PubMed ID: 35843263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRD4S interacts with viral E2 protein to limit human papillomavirus late transcription.
    Yigitliler A; Renner J; Simon C; Schneider M; Stubenrauch F; Iftner T
    J Virol; 2021 May; 95(11):. PubMed ID: 33731454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
    Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
    Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR2-BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model.
    Lei JH; Zhang L; Wang Z; Peltier R; Xie Y; Chen G; Lin S; Miao K; Deng CX; Sun H
    Front Immunol; 2022; 13():861221. PubMed ID: 35547739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CircFAM64A enhances cellular processes in triple-negative breast cancer by targeting the miR-149-5p/CDT1 axis.
    Maimaiti Y; Zhang N; Zhang Y; Zhou J; Song H; Wang S
    Environ Toxicol; 2022 May; 37(5):1081-1092. PubMed ID: 35048507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle-related genes and miRNAs in triple-negative breast cancer cells.
    Tafti A; Shojaei S; Zali H; Karima S; Mohammadi-Yeganeh S; Mondanizadeh M
    Mol Carcinog; 2023 Dec; 62(12):1960-1973. PubMed ID: 37787375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to ATR inhibitor treatment.
    Garikapati K; Young IC; Hong S; Rai P; Jain C; Briegel KJ
    Oncogene; 2024 Mar; 43(12):851-865. PubMed ID: 38297083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes.
    Dooley KE; Warburton A; McBride AA
    mBio; 2016 Sep; 7(5):. PubMed ID: 27624132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest.
    Ottinger M; Christalla T; Nathan K; Brinkmann MM; Viejo-Borbolla A; Schulz TF
    J Virol; 2006 Nov; 80(21):10772-86. PubMed ID: 16928766
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
    Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
    Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
    Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P
    Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.